Ovarian function suppression: To what extent is it necessary for premenopausal patients with operable hormone-sensitive breast cancer?
The use of tamoxifen is conventional adjuvant hormone therapy in premenopausal patients with receptor-positive breast cancer. Clinical trials demonstrating the benefits of ovarian function suppression as adjuvant treatment had an ambiguous interpretation. There is no scientific evidence favoring the...
Saved in:
Main Author: | P. V. Koposov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-09-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/446 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE ROLE OF OVARIAN SUPPRESSION IN THE TREATMENT OF EARLY-STAGE HORMONE-SENSITIVE BREAST CANCER
by: I. A. Koroleva, et al.
Published: (2018-08-01) -
Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a cohort study
by: Yongsheng Wang, et al.
Published: (2025-08-01) -
Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer
by: E. M. Slonimskaya, et al.
Published: (2018-10-01) -
Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning
by: Oana Maria Burciu, et al.
Published: (2025-07-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01)